Screen Reader Mode Icon Check SCREEN READER MODE to make this survey compatible with screen readers. Business impact of COVID -19 (October/November 2020) Question Title * 1. Company name (Any data will be aggregated and anonymised however this question allows us to avoid any duplicate responses) OK Question Title * 2. Approximately, how many staff does your business employ? 0-10 10-50 50-250 250+ OK Question Title * 3. What product area does your business operate in? (Choose all that apply) Anaesthetic and Respiratory Technology Assistive Technology Biotechnology Cardiovascular and Vascular Devices Dental and Maxillofacial Technology Digital Health Drug Delivery Education and Training Emergency Care Products Hospital Hardware, including Ambulatory Implantable devices - n.e.c. In Vitro Diagnostic Technology (routine testing) In Vitro Diagnostic Technology (COVID-19 testing) Infection Control Manufacturing, Components, Packaging and Supply Chain Medical Imaging/Ultrasound Equipment and Materials Mobility Access Neurology Obstetric, Neonatal, Paediatric and Gynaecological Ophthalmic Devices/Equipment Orthopaedic Devices Professional Services, Consultancy Radiotherapy Equipment Reusable diagnostic or analytic equipment - n.e.c. Single Use Technology - n.e.c. Surgical Instruments (reusable) - n.e.c. Wound Care and Management Other (please specify) OK Question Title * 4. What product area does your business operate in? (Choose all that apply) Anaesthetic and Respiratory Technology Assistive Technology Biotechnology Cardiovascular and Vascular Devices Dental and Maxillofacial Technology Digital Health Drug Delivery Education and Training Emergency Care Products Hospital Hardware, including Ambulatory Implantable devices - n.e.c. In Vitro Diagnostic Technology (routine testing) In Vitro Diagnostic Technology (COVID-19 testing) Infection Control Manufacturing, Components, Packaging and Supply Chain Medical Imaging/Ultrasound Equipment and Materials Mobility Access Neurology Obstetric, Neonatal, Paediatric and Gynaecological Ophthalmic Devices/Equipment Orthopaedic Devices Professional Services, Consultancy Radiotherapy Equipment Reusable diagnostic or analytic equipment - n.e.c. Single Use Technology - n.e.c. Surgical Instruments (reusable) - n.e.c. Wound Care and Management Other (please specify) OK Question Title * 5. How big of an impact has the COVID-19 pandemic had on your organisation in October and November? Minimal Considerably increased profitability Increased profitability Decreased profitability Considerably decreased profitability to the point the business may not survive OK Question Title * 6. We are aiming to asses the impact on elective procedures during the pandemic. Compared to the same time periods in 2019, what has been the impact on the product orders that your elective business has received? Increased by over 100% Increased by between 50-99% Increased by between 25-49% Increased by between 1-24% no change Decreased by between 1-24% Decreased by between 25-49% Decreased by between 50-99% Decreased by 100% (i.e. orders are close to zero) Not sure Our products are not used in elective procedures October 2020 October 2020 Increased by over 100% October 2020 Increased by between 50-99% October 2020 Increased by between 25-49% October 2020 Increased by between 1-24% October 2020 no change October 2020 Decreased by between 1-24% October 2020 Decreased by between 25-49% October 2020 Decreased by between 50-99% October 2020 Decreased by 100% (i.e. orders are close to zero) October 2020 Not sure October 2020 Our products are not used in elective procedures November 2020 November 2020 Increased by over 100% November 2020 Increased by between 50-99% November 2020 Increased by between 25-49% November 2020 Increased by between 1-24% November 2020 no change November 2020 Decreased by between 1-24% November 2020 Decreased by between 25-49% November 2020 Decreased by between 50-99% November 2020 Decreased by 100% (i.e. orders are close to zero) November 2020 Not sure November 2020 Our products are not used in elective procedures OK Question Title * 7. During October and November, did you furlough any staff? Yes No OK Question Title * 8. If yes, how many staff were furloughed? OK Question Title * 9. Can you provide details of how many jobs may be at risk if without continued support? OK Question Title * 10. The Government has outlined several measures by which businesses, of all sizes, can obtain financing help. We would like to know which finance support initiatives your business used in October and November. Deferring VAT and Income Tax payments Business rates relief to qualifying businesses Business support grant funds Coronavirus Bounce Back Loan Coronavirus Future Fund Coronavirus Business Interruption Loan Scheme Coronavirus Large Business Interruption Loan Scheme COVID-19 Corporate Financing Facility N/A Other (please specify) OK Question Title * 11. Is there any additional support UK Government can provide to help support your business? OK Question Title * 12. Have you seen any changes to your cost base in October and November? Increase in raw material/component costs Increase in freight costs Increase in local logistics costs (delivery points) Increase in administration costs No Change Decrease in costs Other OK Question Title * 13. Which, if any, of these challenges has your business faced during October and November? Limited cash flow due to late payments Limited cash flow due to a decrease in orders Increased cost to serve Reduced supply of raw materials/component parts Inability to maintain/service/install technology Increased staff absence due to illness Increased staff absence due to limited childcare We have not faced challenges Other (please specify) OK Question Title * 14. There are a number of processes involved in supplying HealthTech to the UK healthcare market. How if at all have you seen these change during October and November? Deteriorated Significantly Deteriorated slightly No change Improved slightly Improved significantly N/A Regulatory approval Regulatory approval Deteriorated Significantly Regulatory approval Deteriorated slightly Regulatory approval No change Regulatory approval Improved slightly Regulatory approval Improved significantly Regulatory approval N/A Assessment of a products value Assessment of a products value Deteriorated Significantly Assessment of a products value Deteriorated slightly Assessment of a products value No change Assessment of a products value Improved slightly Assessment of a products value Improved significantly Assessment of a products value N/A Speed of purchasing decisions Speed of purchasing decisions Deteriorated Significantly Speed of purchasing decisions Deteriorated slightly Speed of purchasing decisions No change Speed of purchasing decisions Improved slightly Speed of purchasing decisions Improved significantly Speed of purchasing decisions N/A Communication between different parts of the supply chain Communication between different parts of the supply chain Deteriorated Significantly Communication between different parts of the supply chain Deteriorated slightly Communication between different parts of the supply chain No change Communication between different parts of the supply chain Improved slightly Communication between different parts of the supply chain Improved significantly Communication between different parts of the supply chain N/A Clarity of volume requirements Clarity of volume requirements Deteriorated Significantly Clarity of volume requirements Deteriorated slightly Clarity of volume requirements No change Clarity of volume requirements Improved slightly Clarity of volume requirements Improved significantly Clarity of volume requirements N/A Speed of adoption of innovative technologies Speed of adoption of innovative technologies Deteriorated Significantly Speed of adoption of innovative technologies Deteriorated slightly Speed of adoption of innovative technologies No change Speed of adoption of innovative technologies Improved slightly Speed of adoption of innovative technologies Improved significantly Speed of adoption of innovative technologies N/A Other (please specify) OK Question Title * 15. Below is a list of challenges we are aware of that HealthTech companies may face in the next 12 months. Please rank them where 1 is the biggest challenge your business will face and 8 is the smallest. 1 2 3 4 5 6 7 8 N/A Generating income to restore profitability N/A 1 2 3 4 5 6 7 8 N/A The nature of the healthcare system recovery including any second wave N/A 1 2 3 4 5 6 7 8 N/A Staff absence due to illness or self isolation N/A 1 2 3 4 5 6 7 8 N/A Staff absence due to limited childcare N/A 1 2 3 4 5 6 7 8 N/A Staff cohesiveness due to flexible working arrangements N/A 1 2 3 4 5 6 7 8 N/A Ability to access raw materials/component parts N/A 1 2 3 4 5 6 7 8 N/A Supply continuity through Brexit N/A 1 2 3 4 5 6 7 8 N/A Regulatory transition (either to MDR/IVDR or UK CA mark) N/A OK Question Title * 16. Are there any additional challenges you would like us to be aware of? OK DONE